- Home
- BEAM vs RAMP Comparison
BEAM vs RAMP Comparison
Compare BEAM & RAMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- RAMP
- Stock Information
- Founded
- BEAM 2017
- RAMP 2018
- Country
- BEAM United States
- RAMP United States
- Employees
- BEAM N/A
- RAMP N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- RAMP EDP Services
- Sector
- BEAM Health Care
- RAMP Technology
- Exchange
- BEAM Nasdaq
- RAMP Nasdaq
- Market Cap
- BEAM 1.9B
- RAMP 1.8B
- IPO Year
- BEAM 2020
- RAMP 1987
- Fundamental
- Price
- BEAM $20.62
- RAMP $32.57
- Analyst Decision
- BEAM Strong Buy
- RAMP Buy
- Analyst Count
- BEAM 11
- RAMP 8
- Target Price
- BEAM $48.90
- RAMP $39.38
- AVG Volume (30 Days)
- BEAM 2.6M
- RAMP 388.9K
- Earning Date
- BEAM 08-05-2025
- RAMP 08-06-2025
- Dividend Yield
- BEAM N/A
- RAMP N/A
- EPS Growth
- BEAM N/A
- RAMP N/A
- EPS
- BEAM N/A
- RAMP N/A
- Revenue
- BEAM $63,578,000.00
- RAMP $745,580,000.00
- Revenue This Year
- BEAM N/A
- RAMP $9.94
- Revenue Next Year
- BEAM $17.18
- RAMP $9.35
- P/E Ratio
- BEAM N/A
- RAMP N/A
- Revenue Growth
- BEAM N/A
- RAMP 13.03
- 52 Week Low
- BEAM $13.53
- RAMP $21.45
- 52 Week High
- BEAM $35.25
- RAMP $36.08
- Technical
- Relative Strength Index (RSI)
- BEAM 55.12
- RAMP 49.71
- Support Level
- BEAM $19.40
- RAMP $32.48
- Resistance Level
- BEAM $22.76
- RAMP $33.62
- Average True Range (ATR)
- BEAM 1.32
- RAMP 0.58
- MACD
- BEAM -0.01
- RAMP -0.13
- Stochastic Oscillator
- BEAM 38.07
- RAMP 21.86
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.
About RAMP LiveRamp Holdings Inc.
LiveRamp Holdings Inc is a global technology company that helps companies build enduring brand and business value by collaborating responsibly with data. A groundbreaking leader in consumer privacy, data ethics and foundational identity, LiveRamp offers a connected customer view with clarity and context while protecting brand and consumer trust.